logo
Plus   Neg
Share
Email

EU Approves Amgen's Osteoporosis Drug Evenity

Amgen (AMGN) and UCB said Thursday that the European Commission approved Evenity or romosozumab for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Evenity is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption or bone loss.

The company plans to launch Evenity in the European Economic Area in the first half of 2020.

Evenity is now approved in 37 countries, including the U.S., Japan, Canada and Australia.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>